Statistik Asas
| CIK | 1411158 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Arctos NorthStar Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| July 11, 2016 |
ANAC / Anacor Pharmaceuticals, Inc. / Baker Brothers Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 v443979sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 3)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 032420101 (CUSIP Number) June 30, 2016 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| July 5, 2016 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-34973 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| June 24, 2016 |
Anacor Pharmaceuticals S-8 POS S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration No. |
|
| June 24, 2016 |
Anacor Pharmaceuticals S-8 POS S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration No. |
|
| June 24, 2016 |
Anacor Pharmaceuticals S-8 POS S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration No. |
|
| June 24, 2016 |
Anacor Pharmaceuticals S-8 POS S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration No. |
|
| June 24, 2016 |
Anacor Pharmaceuticals S-8 POS S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration No. |
|
| June 24, 2016 |
Anacor Pharmaceuticals S-8 POS S-8 POS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration No. |
|
| June 24, 2016 |
Anacor Pharmaceuticals POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration Statement File No. 333-190819 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-190819 UNDER THE SECURITIES ACT OF 1933 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| June 24, 2016 |
Anacor Pharmaceuticals POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration Statement File No. |
|
| June 24, 2016 |
Anacor Pharmaceuticals POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post-Effective Amendment No. 1 to Form S-3 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration Statement File No. 333-185486 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-185486 UNDER THE SECURITIES ACT OF 1933 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| June 24, 2016 |
Anacor Pharmaceuticals POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 24, 2016 Registration Statement File No. |
|
| June 24, 2016 |
Anacor Pharmaceuticals FINAL AMENDMENT TO SCHEDULE 14D9 Final Amendment to Schedule 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 24, 2016 |
Anacor Pharmaceuticals FINAL AMENDMENT TO SCHEDULE TO SC TO-T/A 1 d216360dsctota.htm FINAL AMENDMENT TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) ANACOR PHARMACEUTICALS, INC. (Name of Subject Company) QUATTRO MERGER SUB INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Fi |
|
| June 24, 2016 |
8-K 1 d209119d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2016 ANACOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction ( |
|
| June 24, 2016 |
EX-4.2 5 d209119dex42.htm EX-4.2 Exhibit 4.2 SUPPLEMENTAL INDENTURE SUPPLEMENTAL INDENTURE (the “Supplemental Indenture”), dated as of June 24, 2016, to the Indenture (defined below) by and among Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Wells Fargo Bank, National Association, a national banking association, as Trustee under the Indenture (the “Trustee”). WITNESSETH |
|
| June 24, 2016 |
AMENDED AND RESTATED BY-LAWS ANACOR PHARMACEUTICALS, INC. ARTICLE I EX-3.2 3 d209119dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ANACOR PHARMACEUTICALS, INC. ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE – The address, including street, number, city, and county, of the registered office of Anacor Pharmaceuticals, Inc. (the “Corporation”) in the State of Delaware is the Corporation Trust Center, 1209 Orange Street, City of Wilmington, County of New |
|
| June 24, 2016 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ANACOR PHARMACEUTICALS, INC. ARTICLE I EX-3.1 2 d209119dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of ANACOR PHARMACEUTICALS, INC. ARTICLE I The name of the corporation is Anacor Pharmaceuticals, Inc. (the “Corporation”). ARTICLE II The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is the Corporation Trust Center, 1209 Orange |
|
| June 24, 2016 |
PFIZER COMPLETES ACQUISITION OF ANACOR EX-99.1 Exhibit 99.1 PFIZER COMPLETES ACQUISITION OF ANACOR Tender offer for all of the outstanding shares of Anacor common stock expired as scheduled immediately after 11:59 p.m., New York City time, on June 23, 2016 Pfizer and Anacor begin joint operations on June 24, 2016 New York, NY, June 24, 2016 ? Pfizer Inc. (NYSE: PFE) today announced that it has completed its acquisition of Anacor Pharma |
|
| June 24, 2016 |
EX-4.1 Exhibit 4.1 SUPPLEMENTAL INDENTURE SUPPLEMENTAL INDENTURE (the ?Supplemental Indenture?), dated as of June 24, 2016, to the Indenture (defined below) by and among Anacor Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Wells Fargo Bank, National Association, a national banking association, as Trustee under the Indenture (the ?Trustee?). WITNESSETH WHEREAS, the Company has |
|
| June 8, 2016 |
AMENDED AND RESTATED BYLAWS ANACOR PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ANACOR PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place Of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 5 Section 7. Notice Of Meetings 6 Section 8. |
|
| June 8, 2016 |
Anacor Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 7, 2016 |
Anacor Pharmaceuticals SCHEDULE 14D-9/A SC 14D9/A 1 dp66391sc14d9a.htm SCHEDULE 14D-9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ANACOR PHARMACEUTICALS, INC. (Name of Subject Company) ANACOR PHARMACEUTICALS, INC. (Name of Person(s) Filing Statement) Common stoc |
|
| June 7, 2016 |
Anacor Pharmaceuticals AMENDMENT NO. 1 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) ANACOR PHARMACEUTICALS, INC. (Name of Subject Company) QUATTRO MERGER SUB INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per share (Title |
|
| May 26, 2016 |
CONFIDENTIALITY AGREEMENT April 19, 2016 EX-99.(e)(2) Exhibit (e)(2) CONFIDENTIALITY AGREEMENT April 19, 2016 Pfizer Inc. 235 East 42nd Street New York, New York 10017 Attn: Deborah Baron Ladies and Gentlemen: In connection with your consideration of a possible transaction involving Anacor Pharmaceuticals, Inc. (the ?Company?) and Pfizer Inc. (?Pfizer?) (the ?Transaction?), it is expected that each party may furnish or otherwise make ava |
|
| May 26, 2016 |
Anacor Pharmaceuticals SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ANACOR PHARMACEUTICALS, INC. (Name of Subject Company) ANACOR PHARMACEUTICALS, INC. (Name of Person(s) Filing Statement) Common stock, par value $0.001 per share (Title of Class of |
|
| May 26, 2016 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of ANACOR PHARMACEUTICALS, INC. a Delaware corporation at $99.25 NET PER SHARE Pursuant to the Offer to Purchase dated May 26, 2016 by QUATTRO MERGER SUB INC. a wholly-owned subsidiary of PFIZER INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY, IMMEDIATELY AFTER 11:59 P.M., NEW |
|
| May 26, 2016 |
EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Anacor Pharmaceuticals, Inc. at $99.25 Net Per Share by Quattro Merger Sub Inc. a wholly-owned subsidiary of Pfizer Inc. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY, IMMEDIATELY AFTER 11:59 P.M. NEW YORK CITY TIME ON THURSDAY, JUNE 23, 2016, UNLESS THE OFFE |
|
| May 26, 2016 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of ANACOR PHARMACEUTICALS, INC. a Delaware corporation at $99.25 NET PER SHARE Pursuant to the Offer to Purchase dated May 26, 2016 by QUATTRO MERGER SUB INC. a wholly-owned subsidiary of PFIZER INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY, IMMEDIATELY AFTER 11:59 P.M., NEW |
|
| May 26, 2016 |
EX-99.(A)(1)(B) 3 d359116dex99a1b.htm EX-99.(A)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of ANACOR PHARMACEUTICALS, INC. a Delaware corporation at $99.25 NET PER SHARE Pursuant to the Offer to Purchase Dated May 26, 2016 by QUATTRO MERGER SUB INC. a wholly-owned subsidiary of PFIZER INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY, IMMEDI |
|
| May 26, 2016 |
Anacor Pharmaceuticals SC TO-T SC TO-T 1 d359116dsctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ANACOR PHARMACEUTICALS, INC. (Name of Subject Company) QUATTRO MERGER SUB INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 |
|
| May 26, 2016 |
CONFIDENTIALITY AGREEMENT April 19, 2016 EX-99.(d)(2) Exhibit (d)(2) CONFIDENTIALITY AGREEMENT April 19, 2016 Pfizer Inc. 235 East 42nd Street New York, New York 10017 Attn: Deborah Baron Ladies and Gentlemen: In connection with your consideration of a possible transaction involving Anacor Pharmaceuticals, Inc. (the ?Company?) and Pfizer Inc. (?Pfizer?) (the ?Transaction?), it is expected that each party may furnish or otherwise make ava |
|
| May 26, 2016 |
EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely pursuant to the Offer to Purchase, dated May 26, 2016, and the related Letter of Transmittal and any amendments or sup |
|
| May 26, 2016 |
EX-99.(a)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of ANACOR PHARMACEUTICALS, INC. a Delaware corporation at $99.25 NET PER SHARE Pursuant to the Offer to Purchase dated May 26, 2016 by QUATTRO MERGER SUB INC. a wholly-owned subsidiary of PFIZER INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT THE END OF THE DAY, IMMEDIATELY AFTER 11:59 P.M., NE |
|
| May 19, 2016 |
Anacor Pharmaceuticals SCHEDULE 14D-9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ANACOR PHARMACEUTICALS, INC. (Name of Subject Company) ANACOR PHARMACEUTICALS, INC. (Name of Person(s) Filing Statement) Common stock, par value $0.001 per share (Title of Class of Securities) 03242 |
|
| May 19, 2016 |
SPECIFIED CORPORATE TRANSACTION NOTICE Exhibit 99.1 May 19, 2016 To: Holders of Anacor Pharmaceuticals, Inc. 2.00% Convertible Senior Notes due 2021 (CUSIP: 032420 AC5) and 2.00% Convertible Senior Notes due 2023 (CUSIP: 032420 AD3) Wells Fargo Bank, National Association as Trustee and Conversion Agent 333 S. Grand Ave., 5th floor, Suite 5A Los Angeles, CA 90071 Attention: Anacor Pharmaceuticals Administrator Re: Specified Corporate Tr |
|
| May 16, 2016 |
Anacor Pharmaceuticals SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ANACOR PHARMACEUTICALS, INC. (Name of Subject Company) QUATTRO MERGER SUB INC. (Offeror) PFIZER INC. (Parent of Offeror) (Names of Filing Persons) Common stock, par value $0.001 per share (Title of Class of Securi |
|
| May 16, 2016 |
Pfizer Tweets (@Pfizer_news), May 16, 2016 Exhibit 99.1 Pfizer Tweets (@Pfizernews), May 16, 2016 Pfizer to acquire Anacor on.pfizer.com/1rOROow |
|
| May 16, 2016 |
Anacor Pharmaceuticals FORM SC14D9C SC14D9C 1 dp65734sc14d9c.htm FORM SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ANACOR PHARMACEUTICALS, INC. (Name of Subject Company) ANACOR PHARMACEUTICALS, INC. (Name of Person(s) Filing Statement) Common stock, par value $0.001 per |
|
| May 16, 2016 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of May 14, 2016 among ANACOR PHARMACEUTICALS, INC., PFIZER INC. and QUATTRO MERGER SUB INC. TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 10 ARTICLE 2 THE OFFER Section 2.01. The Offer 10 Section 2.02. Company Action 13 ARTICLE 3 THE MERGER S |
|
| May 16, 2016 |
8-K 1 dp657328k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdictio |
|
| May 16, 2016 |
Exhibit 99.1 Pfizer to Acquire Anacor ? Strong fit with Pfizer?s Inflammation and Immunology portfolio ? Expected to enhance near-term revenue growth for the innovative business ? Anacor?s flagship asset, crisaborole, has a New Drug Application under review by the U.S. Food and Drug Administration (FDA), is a differentiated non-steroidal topical PDE4 inhibitor with compelling clinical data, and if |
|
| May 16, 2016 |
EX-99.1 Exhibit 99.1 Pfizer to Acquire Anacor ? Strong fit with Pfizer?s Inflammation and Immunology portfolio ? Expected to enhance near-term revenue growth for the innovative business ? Anacor?s flagship asset, crisaborole, has a New Drug Application under review by the U.S. Food and Drug Administration (FDA), is a differentiated non-steroidal topical PDE4 inhibitor with compelling clinical data |
|
| May 16, 2016 |
Anacor Pharmaceuticals FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2016 (May 14, 2016) PFIZER INC. (Exact name of registrant as specified in its charter) DELAWARE (State or Other Jurisdiction of Incorporation) 1-3619 13-5315170 (Commi |
|
| May 10, 2016 |
Anacor Pharmaceuticals 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34973 An |
|
| May 10, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 10, 2016 |
ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS Palo Alto, CA ? May 10, 2016 ? Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended March 31, 2016. ?This is an exciting time for Anacor. In January 2016, we submitted our NDA for crisaborole topical ointment, 2%, to the FDA ahead of schedule. The FDA has accepted the |
|
| April 29, 2016 |
Anacor Pharmaceuticals DEF 14A DEF 14A 1 a2228340zdef14a.htm DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the |
|
| April 6, 2016 |
Exhibit 4.1 ANACOR PHARMACEUTICALS, INC. (Company) WELLS FARGO BANK, NATIONAL ASSOCIATION (Trustee) 2.00% Convertible Senior Notes due 2023 INDENTURE Dated as of April 6, 2016 ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 References to Interest 13 Section 1.03 Acts of Holders 13 ARTICLE 2. THE NOTES 15 Section 2.01 Title and Terms; Pay |
|
| April 6, 2016 |
Exhibit 10.1 Opening Transaction To: Anacor Pharmaceuticals, Inc. 1020 East Meadow Circle Palo Alto, CA 94303 From: Citigroup Global Markets Inc. Re: Base Capped Call Transaction Date: March 31, 2016 Dear Ladies and Gentlemen: The purpose of this communication (this ?Confirmation?) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified |
|
| April 6, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 1, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 1, 2016 |
Exhibit 99.1 ANACOR PHARMACEUTICALS, INC. ANNOUNCES PRICING OF OFFERING OF $250 MILLION OF 2.00% CONVERTIBLE SENIOR NOTES DUE 2023 Palo Alto, CA, March 31, 2016? Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2023 (the ?Convertible Notes?) in a private placement under the Secur |
|
| March 30, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 a16-755528k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction |
|
| March 30, 2016 |
Exhibit 99.1 ANACOR PHARMACEUTICALS, INC. ANNOUNCES PROPOSED OFFERING OF $250 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2023 Palo Alto, CA, March 30, 2016? Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) announced today that it intends to offer, subject to market and other considerations, $250,000,000 aggregate principal amount of Convertible Senior Notes due 2023 (the ?Convertible Notes?) in a private |
|
| March 22, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 22, 2016 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR CRISABOROLE TOPICAL OINTMENT, 2% FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS Palo Alto, CA ? March 22, 2016 ? Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Anacor?s New Drug Application (NDA) seeking approval of crisaborole topica |
|
| February 29, 2016 |
Anacor Pharmaceuticals 10-K (Annual Report) Use these links to rapidly review the document TABLE OF CONTENTS ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTIO |
|
| February 29, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 29, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 29, 2016 |
ANACOR PHARMACEUTICALS REPORTS 2015 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS 2015 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS ? Submitted NDA to the FDA on January 7, 2016 seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults ? Recognized $69.7 million in total K |
|
| February 24, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 16, 2016 |
ANAC / Anacor Pharmaceuticals, Inc. / Palo Alto Investors, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 10, 2016 |
ANAC / Anacor Pharmaceuticals, Inc. / Baker Brothers Advisors LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2016 |
ANAC / Anacor Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment anacorpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Anacor Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 032420101 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the |
|
| February 5, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ?????????? FORM 8-K ?????????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 2, 2016 ?????????? Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) ?????????? Delaware 001-34973 25-1854385 (State or Ot |
|
| January 11, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2016 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 11, 2016 |
Investor Presentation January 2016 Exhibit 99.1 Investor Presentation January 2016 Cautionary Statements This presentation contains forward-looking statements, including statements regarding the results of our clinical trials, the safety and efficacy of our approved product and product development candidates, the timing of the approval of our product development candidates, the commercial success of KERYDIN and the timing and poten |
|
| January 11, 2016 |
Exhibit 99.2 ANACOR PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR CRISABOROLE TOPICAL OINTMENT, 2% FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS Palo Alto, CA ? January 7, 2016 ? Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical |
|
| November 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Anacor Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) DAVID L. STEPP VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CALIFORNIA 94304 TELEPHONE: (650) 561-9580 (Name, Address and Telephone Number of P |
|
| November 3, 2015 |
Anacor Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2015 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 3, 2015 |
ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS ? Recognized $21.1 million in total KERYDIN? revenue in the third quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 18.8% over the second quarter of 2015 ? Top-line results from the long-term safety study of crisaborole topical ointment, 2%, in patients with mild-to-moderate atopic derm |
|
| November 3, 2015 |
Exhibit 99.2 ANACOR PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM LONG-TERM SAFETY STUDY OF CRISABOROLE TOPICAL OINTMENT, 2% IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS ? Crisaborole, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor, demonstrated a safety profile consistent with that seen in the Phase 3 pivotal studies when used intermittently for up to 12 months ? Anacor |
|
| August 21, 2015 |
Anacor Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2015 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commi |
|
| August 14, 2015 |
ANAC / Anacor Pharmaceuticals, Inc. / GLAXOSMITHKLINE PLC Activist Investment SC 13D/A 1 glaxoanacorsc13da3-0812.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ANACOR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 032420 101 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW |
|
| August 7, 2015 |
As filed with the Securities and Exchange Commission on August 7, 2015 Registration No. |
|
| August 6, 2015 |
Anacor Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commis |
|
| August 6, 2015 |
ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS ? Recognized $17.8 million in total KERYDIN? revenue in the second quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 47.5% over the first quarter of 2015 ? Crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor, achieved statistically signific |
|
| July 13, 2015 |
Anacor Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2015 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commiss |
|
| July 13, 2015 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM TWO PHASE 3 PIVOTAL STUDIES OF CRISABOROLE TOPICAL OINTMENT, 2% IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS ? Crisaborole, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor, achieved statistically significant results on all primary and secondary endpoints in both studies and demonstrated a safety pro |
|
| June 29, 2015 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES AMENDMENT TO KERYDIN COMMERCIALIZATION AGREEMENT ? Increased investment in commercial activities in 2015 ? Increased minimum profit-sharing payments to Anacor for 2016 ? New minimum profit-sharing payments to Anacor for 2017 ? Reduced price for Anacor?s KERYDIN repurchase option in 2017 Palo Alto, CA ? June 29, 2015 ? Anacor Pharmaceuticals, Inc. (NASD |
|
| June 29, 2015 |
Anacor Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2015 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commiss |
|
| June 11, 2015 |
Anacor Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2015 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commissi |
|
| June 3, 2015 |
Anacor Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ?????????? Form 8-K ?????????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2015 ?????????? Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ?????????? Delaware 001-34973 25-1854385 (State or ot |
|
| June 3, 2015 |
Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Ryan T. |
|
| June 3, 2015 |
Exhibit 99.1 Anacor pharmaceuticals NAMES GRAEME BELL AS new Executive Vice President and CHIEF FINANCIAL OFFICER Bell brings more than 20 years expertise in global finance, M&A and business development Palo Alto, CA ? June 1, 2015 ? Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that Graeme Bell will join Anacor as its new Executive Vice President and Chief Financial Officer. Mr. Bel |
|
| May 6, 2015 |
Anacor Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2015 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commissio |
|
| May 6, 2015 |
ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS Palo Alto, CA ? May 6, 2015 ? Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended March 31, 2015. ?We continue to work with our partner Sandoz to optimize the commercial opportunity for KERYDIN? and believe, based on the continued growth in prescriptions, that we are |
|
| April 30, 2015 |
Anacor Pharmaceuticals DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 12, 2015 |
Anacor Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2015 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commis |
|
| March 12, 2015 |
ANACOR PHARMACEUTICALS REPORTS 2014 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS 2014 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Palo Alto, CA March 12, 2015 Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2014. 2014 was a significant year for Anacor. Our first drug, KERYDIN®, was approved by the FDA for the topical treatment of onychomycosis |
|
| February 20, 2015 |
Amendment No. 2 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Anacor Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) DAVID L. STEPP VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CALIFORNIA 94304 TELEPHONE: (650) 561-9580 (Name, A |
|
| February 18, 2015 |
ANAC / Anacor Pharmaceuticals, Inc. / Palo Alto Investors, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 17, 2015 |
ANAC / Anacor Pharmaceuticals, Inc. / Baker Brothers Advisors LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 17, 2015 |
ANAC / Anacor Pharmaceuticals, Inc. / KINGDON CAPITAL MANAGEMENT, L.L.C. Passive Investment SC 13G/A 1 d636098613ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 13, 2015 |
ANAC / Anacor Pharmaceuticals, Inc. / GLAXOSMITHKLINE PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ANACOR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 032420 101 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS Telephone: +44 (0)208 047 5000 Na |
|
| February 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2015 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commi |
|
| January 12, 2015 |
Exhibit 10.1 SIXTH AMENDMENT TO LEASE This Sixth Amendment to Lease (“Sixth Amendment”), dated as of January 8, 2015 (the “Effective Date”), is entered into by and between Balzer Family Investments, L.P., a California limited partnership (“Lessor”), and Anacor Pharmaceuticals, Inc., a Delaware corporation (“Lessee”). RECITALS A. Lessor and Lessee entered into that certain Lease dated October 16, 2 |
|
| January 9, 2015 |
ANAC / Anacor Pharmaceuticals, Inc. CORRESP - - January 9, 2015 Re: Anacor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed March 17, 2014 File No. 001-34973 Jim B. Rosenberg, Senior Assistant Chief Accountant Sasha Parikh, Senior Staff Accountant Keira Nakada, Senior Staff Accountant Bryan Pitko, Special Counsel Johnny Gharib, Staff Attorney Division of Corporation Finance Securities and Exchange Commission 100 |
|
| December 16, 2014 |
ANAC / Anacor Pharmaceuticals, Inc. CORRESP - - December 16, 2014 Re: Anacor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed March 17, 2014 File No. 001-34973 Jim B. Rosenberg, Senior Assistant Chief Accountant Sasha Parikh, Senior Staff Accountant Keira Nakada, Senior Staff Accountant Bryan Pitko, Special Counsel Johnny Gharib, Staff Attorney Division of Corporation Finance Securities and Exchange Commission 1 |
|
| November 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2014 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Comm |
|
| November 6, 2014 |
ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS Palo Alto, CA — November 6, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended September 30, 2014. “2014 continues to be a productive year for Anacor. In the third quarter we achieved three important milestones — our first drug, KERYDINTM, was approved by the |
|
| October 16, 2014 |
Exhibit 4.1 ANACOR PHARMACEUTICALS, INC. (Company) WELLS FARGO BANK, NATIONAL ASSOCIATION (Trustee) 2.00% Convertible Senior Notes due 2021 INDENTURE Dated as of October 16, 2014 ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 References to Interest 13 Section 1.03 Acts of Holders 13 ARTICLE 2. THE NOTES 15 Section 2.01 Title and Terms; |
|
| October 16, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2014 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation or Org |
|
| October 16, 2014 |
Anacor Pharmaceuticals, Inc. 2.00% Convertible Senior Notes due 2021 Registration Rights Agreement Exhibit 4.3 Anacor Pharmaceuticals, Inc. 2.00% Convertible Senior Notes due 2021 Registration Rights Agreement This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is dated as of October 16, 2014 by and between (A) Anacor Pharmaceuticals, Inc., a Delaware corporation (together with its successors, the “Company”), and (B) Venrock Healthcare Capital Partners, L.P., a limited partnership organized u |
|
| October 10, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2014 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation or Orga |
|
| October 10, 2014 |
Exhibit 99.1 ANACOR PHARMACEUTICALS, INC. ANNOUNCES PRICING OF OFFERING OF $75 MILLION OF 2.00% CONVERTIBLE SENIOR NOTES DUE 2021 Palo Alto, CA, October 9, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) announced today the pricing of its offering of $75,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2021 (the “Convertible Notes”) in a private placement under the Secur |
|
| October 8, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2014 Anacor Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-34973 25-1854385 (State or Other Jurisdiction of Incorporation or Orga |
|
| October 8, 2014 |
Exhibit 99.1 ANACOR PHARMACEUTICALS, INC. ANNOUNCES PROPOSED OFFERING OF $70 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2021 Palo Alto, CA, October 8, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) announced today that it intends to offer, subject to market and other considerations, $70,000,000 aggregate principal amount of Convertible Senior Notes due 2021 (the “Convertible Notes”) in a private |
|
| October 3, 2014 |
Entry into a Material Definitive Agreement 8-K 1 a14-2188718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2014 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdi |
|
| September 22, 2014 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES COMMERCIAL LAUNCH OF KERYDIN (TAVABOROLE) TOPICAL SOLUTION, 5% IN THE UNITED STATES Palo Alto, CA — September 22, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced the U.S. launch of Anacor’s FDA-approved drug KERYDINTM (tavaborole) topical solution, 5% by Sandoz Inc., a Novartis company. KERYDIN is the first oxaborole antifungal indic |
|
| September 22, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 a14-2129018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2014 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdi |
|
| September 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2014 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Co |
|
| September 12, 2014 |
ANACOR PHARMACEUTICALS APPOINTS WENDELL WIERENGA TO ITS BOARD OF DIRECTORS Exhibit 99.1 ANACOR PHARMACEUTICALS APPOINTS WENDELL WIERENGA TO ITS BOARD OF DIRECTORS Palo Alto, CA — September 12, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the Company’s 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned f |
|
| September 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) August 29, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| August 7, 2014 |
ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS Palo Alto, CA — August 7, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended June 30, 2014. “2014 has been a significant year for Anacor,” said Paul Berns, President and Chief Executive Officer of Anacor Pharmaceuticals. “The FDA approved our New Drug Applica |
|
| August 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a14-1852618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2014 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdictio |
|
| July 21, 2014 |
Exhibit 99.1 ANACOR PHARMACEUTICALS AND SANDOZ ENTER INTO AN AGREEMENT FOR THE COMMERCIALIZATION OF KERYDINTM IN THE UNITED STATES Anacor Will Host a Conference Call Today at 8:00 a.m. EDT / 5:00 a.m. PDT Palo Alto, CA — July 21, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that it has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which |
|
| July 21, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2014 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commiss |
|
| July 8, 2014 |
EX-99.1 2 a14-167711ex99d1.htm EX-99.1 Exhibit 99.1 FDA APPROVES ANACOR PHARMACEUTICALS’ KERYDIN™ (TAVABOROLE) TOPICAL SOLUTION, 5% FOR THE TREATMENT OF ONYCHOMYCOSIS OF THE TOENAILS Palo Alto, CA — July 8, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for KERYDIN™ (tavaborole) topical solut |
|
| July 8, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2014 Anacor Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34973 25-1854385 (State or other jurisdiction of incorporation) (Commissi |
|
| June 4, 2014 |
S-8 1 a14-146331s8.htm S-8 As filed with the Securities and Exchange Commission on June 4, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 25-1854385 (State or other jurisdiction of incorpora |
|
| June 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2014 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Empl |
|
| June 2, 2014 |
ANACOR PHARMACEUTICALS APPOINTS KEITH R. LEONARD, JR. TO BOARD OF DIRECTORS Exhibit 99.1 ANACOR PHARMACEUTICALS APPOINTS KEITH R. LEONARD, JR. TO BOARD OF DIRECTORS Palo Alto, CA — May 30, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has unanimously appointed Keith R. Leonard, Jr. to serve as a Class I director until the Company’s 2017 annual meeting of shareholders. Mr. Leonard has more than 20 years of experience in the p |
|
| May 7, 2014 |
ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Palo Alto, CA — May 7, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the first quarter ended March 31, 2014. “We made important progress in the first quarter on our two lead programs - Kerydin and AN2728,” said Paul Berns, President and Chief Executive Officer of Anacor Ph |
|
| May 7, 2014 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2014 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Emplo |
|
| April 29, 2014 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 20, 2014 |
ANACOR PHARMACEUTICALS APPOINTS PAUL L. BERNS AS CHIEF EXECUTIVE OFFICER Exhibit 99.1 ANACOR PHARMACEUTICALS APPOINTS PAUL L. BERNS AS CHIEF EXECUTIVE OFFICER Palo Alto, CA — March 19, 2014 — Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that the Company’s Board of Directors has appointed Paul L. Berns, Anacor’s Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately. Mr. Berns succeeds David P |
|
| March 20, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2014 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Em |
|
| March 17, 2014 |
Anacor Pharmaceuticals 10-K (Annual Report) 10-K 1 a2218905z10-k.htm 10-K Use these links to rapidly review the document TABLE OF CONTENTS Anacor Pharmaceuticals, Inc. Form 10-K Index ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fi |
|
| March 13, 2014 |
ANACOR PHARMACEUTICALS REPORTS 2013 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS 2013 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Palo Alto, CA — March 13, 2014 — Anacor Pharmaceuticals (NASDAQ:ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2013. “2013 was a transformational year for Anacor, as we advanced our two late-stage programs and successfully resolved our arbitration with Vale |
|
| March 13, 2014 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2014 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Em |
|
| March 7, 2014 |
EX-99.A Exhibit A JOINT FILING STATEMENT I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the Common Stock of Anacor Pharmaceuticals Inc. is filed on behalf of each of the undersigned. Date: March 7, 2014 /s/ Paul H. Klingenstein Paul H. Klingenstein ABERDARE VENTURES II, L.P. By its General Partner, Aberdare GP II, L.L.C. By: |
|
| March 7, 2014 |
ANAC / Anacor Pharmaceuticals, Inc. / Aberdare Ventures II, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| March 3, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2014 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| March 3, 2014 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES SUCCESSFUL COMPLETION OF END-OF-PHASE 2 MEETING WITH FDA FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS WITH AN2728 Palo Alto, Calif. — February 27, 2014 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has successfully completed an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) for the topical t |
|
| February 14, 2014 |
ANAC / Anacor Pharmaceuticals, Inc. / Baker Brothers Advisors LP - SC 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2014 |
ANAC / Anacor Pharmaceuticals, Inc. / RHO VENTURES IV QP LP Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| February 14, 2014 |
ANAC / Anacor Pharmaceuticals, Inc. / KINGDON CAPITAL MANAGEMENT, L.L.C. Passive Investment SC 13G/A 1 d144832213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2014 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Anacor Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2014 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LL |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ANACOR PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this S |
|
| February 10, 2014 |
EXHIBIT 10.32 ANACOR PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT GRANT NOTICE 2010 EQUITY INCENTIVE PLAN Anacor Pharmaceuticals, Inc. (the “Company”) hereby awards to Participant the number of restricted stock units (“RSUs”) set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth in this Notice, the 2010 Equity Incentive Plan (the “Plan”) |
|
| February 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2014 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| February 5, 2014 |
ANAC / Anacor Pharmaceuticals, Inc. / RHO VENTURES IV QP LP Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| December 10, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| November 13, 2013 |
Schedule 13D Amendment No. 6 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 032420101 (CUSIP numbe |
|
| November 13, 2013 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM AN2728 MUSE STUDY IN PEDIATRIC AND ADOLESCENT PATIENTS WITH ATOPIC DERMATITIS Anacor to Host a Conference Call Today at 5pm ET to Discuss Results Palo Alto, CA — November 12, 2013— Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from its maximal use systemic exposure (MUSE) study of its boron-base |
|
| November 13, 2013 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| November 13, 2013 |
Exhibit 99.2 Preliminary Results from AN2728 Maximal Use Systemic Exposure (MUSE) Study in Pediatric and Adolescent Patients with Mild-to-Moderate Atopic Dermatitis November 12, 2013 Safe Harbor Statement Certain items in this presentation and other matters discussed today or answers that may be given to questions asked could constitute forward-looking statements, including statements regarding th |
|
| November 7, 2013 |
ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Palo Alto, CA — November 7, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) today announced its financial results for the third quarter ended September 30, 2013. “We had an eventful third quarter — we filed an NDA for tavaborole, our most advanced product candidate, and received acceptance for filing from the FDA. In addi |
|
| November 7, 2013 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| October 31, 2013 |
Amendment No.5 to Schedule 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 032420101 (CUSIP num |
|
| October 28, 2013 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT WITH VALEANT PHARMACEUTICALS Valeant to Pay Anacor $142.5 Million to Settle Disputes Related to Dow Pharmaceutical Sciences and Medicis Pharmaceutical Corporation Palo Alto, CA — October 28, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that it has entered into a settlement agreement with Valeant Pharmaceuticals Inter |
|
| October 28, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| October 21, 2013 |
EX-99.1 2 a13-225871ex99d1.htm EX-99.1 Exhibit 99.1 ANACOR PHARMACEUTICALS AWARDED U.S. GOVERNMENT FUNDING TO DISCOVER NEW CLASSES OF SYSTEMIC ANTIBIOTICS Palo Alto, CA – October 21, 2013 – Anacor Pharmaceuticals (NASDAQ:ANAC) today announced it has entered into a research agreement with the United States Department of Defense, Defense Threat Reduction Agency (DTRA) to design and discover new clas |
|
| October 21, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| October 18, 2013 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES FAVORABLE RULING IN ITS ARBITRATION WITH VALEANT PHARMACEUTICALS Anacor Awarded $100 Million in Damages Palo Alto, CA — October 17, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant), successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS |
|
| October 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| October 2, 2013 |
ANACOR PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF TAVABOROLE NDA FOR FILING Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF TAVABOROLE NDA FOR FILING Palo Alto, Calif. – October 1, 2013 – Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its New Drug Application (NDA) for tavaborole, its drug candidate for the topical treatment of onychomycosis, has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is suff |
|
| October 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS E |
|
| September 20, 2013 |
September 20, 2013 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeffrey P. Riedler Matthew Jones Re: Anacor Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 26, 2013 Registration File No. 333-190819 Ladies and Gentlemen: The undersigned registrant hereby requests that the U.S. Securities and Exchange Comm |
|
| September 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IR |
|
| August 26, 2013 |
Statement Regarding Computation of Ratios Exhibit 12.1 Statement Regarding Computation of Ratios Year Ended December 31, Six Months Ended 2008 2009 2010 2011 2012 June 30, 2013 (In thousands, except ratio amounts) Earnings Loss before income taxes $ (21,669 ) $ (24,854 ) $ (10,058 ) $ (47,944 ) $ (56,087 ) $ (29,174 ) Interest expense 1,756 1,663 1,304 1,094 2,415 1,509 Amortization of debt issuance costs 542 771 701 342 552 337 Interest |
|
| August 26, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on August 26, 2013 Registration No. |
|
| August 26, 2013 |
ANACOR PHARMACEUTICALS, INC., Issuer [TRUSTEE], Trustee Dated as of [ ], 20 Debt Securities EXHIBIT 4.10 ANACOR PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate |
|
| August 8, 2013 |
ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Palo Alto, CA — August 8, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the second quarter ended June 30, 2013. “We had a busy second quarter as we finalized preparations for our NDA for tavaborole, which was submitted on July 26th. This is an exciting time at Anacor as we begi |
|
| August 8, 2013 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Em |
|
| July 30, 2013 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES THAT IT HAS SUBMITTED A NEW DRUG APPLICATION TO THE FDA FOR TAVABOROLE Palo Alto, Calif. — July 29, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that on July 26, 2013 it submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavaborole, its drug candidate for the topical treatment of onychomycosis. On |
|
| July 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Emp |
|
| July 12, 2013 |
809,061 Shares Anacor Pharmaceuticals, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) File Number 333-189691 PROSPECTUS 809,061 Shares Anacor Pharmaceuticals, Inc. |
|
| June 28, 2013 |
Table of Contents As filed with the Securities and Exchange Commission on June 28, 2013 Registration No. |
|
| June 12, 2013 |
8-K 1 a13-1473918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Com |
|
| June 12, 2013 |
ANACOR PHARMACEUTICALS SECURES $45 MILLION LOAN FACILITY Exhibit 99.1 ANACOR PHARMACEUTICALS SECURES $45 MILLION LOAN FACILITY Palo Alto, CA — June 12, 2013 —Anacor Pharmaceuticals (NASDAQ: ANAC) announced today that it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $45.0 million in new capital to be distributed in three tranches. Anacor borrowed the first tranche of $30.0 million upon |
|
| June 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Empl |
|
| May 9, 2013 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Emplo |
|
| May 9, 2013 |
ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Palo Alto, CA — May 9, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the first quarter ended March 31, 2013. “It was an eventful first quarter. We reported positive data from our two Phase 3 trials of tavaborole in onychomycosis, and we are on track to file our NDA around the mi |
|
| May 2, 2013 |
ANAC / Anacor Pharmaceuticals, Inc. / RHO VENTURES IV LP - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| May 2, 2013 |
EX-99.1 2 a13-113621ex99d1.htm EX-99.1 Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES CLOSING OF $23 MILLION PUBLIC OFFERING OF COMMON STOCK, INCLUDING FULL EXERCISE OF UNDERWRITERS’ OVER-ALLOTMENT OPTION Palo Alto, CA — May 1, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today the completion of its underwritten public offering of 3,129,890 shares of common stock. In addition, Anacor annou |
|
| May 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Emplo |
|
| April 30, 2013 |
DEF 14A 1 a2214400zdef14a.htm DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary P |
|
| April 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Em |
|
| April 26, 2013 |
PROSPECTUS SUPPLEMENT (To the Prospectus dated December 21, 2012) Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) File Number 333-185486 PROSPECTUS SUPPLEMENT (To the Prospectus dated December 21, 2012) 3,129,890 Shares Common Stock We are offering 3,129,890 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. |
|
| April 26, 2013 |
3,129,890 Shares ANACOR PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT EX-1.1 2 a13-107033ex1d1.htm EX-1.1 Exhibit 1.1 3,129,890 Shares ANACOR PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT April 25, 2013 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 As Representative of the several Underwriters listed in Schedule I hereto Dear Sirs: 1. INTRODUCTORY. Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell, pu |
|
| April 26, 2013 |
ANACOR PHARMACEUTICALS PRICES $20 MILLION PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 ANACOR PHARMACEUTICALS PRICES $20 MILLION PUBLIC OFFERING OF COMMON STOCK Palo Alto, CA — April 26, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has priced an underwritten public offering of 3,129,890 shares of its common stock at a price to the public of $6.39 per share for gross proceeds of $20.0 million. Anacor has also granted the underwriters a 30-day optio |
|
| April 25, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) File Number 333-185486 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this prospectus supplement is not complete and may be changed. |
|
| April 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Emp |
|
| April 10, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Emp |
|
| April 8, 2013 |
ANACOR PHARMACEUTICALS RECEIVES SIGNIFICANT INVESTMENT TO SUPPORT NEGLECTED DISEASE RESEARCH Exhibit 99.1 ANACOR PHARMACEUTICALS RECEIVES SIGNIFICANT INVESTMENT TO SUPPORT NEGLECTED DISEASE RESEARCH Palo Alto, CA — April 8, 2013— Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindne |
|
| April 8, 2013 |
ANACOR PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT April 5, 2013 Exhibit 4.1 ANACOR PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT April 5, 2013 ANACOR PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of April 5, 2013, by and between ANACOR PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and the Bill & Melinda Gates Foundation (the “Foundation”). RECITAL |
|
| April 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Emp |
|
| March 28, 2013 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 DOSE-RANGING STUDY OF AN2728 IN ADOLESCENTS WITH ATOPIC DERMATITIS Anacor Will Host a Conference Call Today 8am ET / 5am PT to Discuss Results Palo Alto, CA — March 21, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based p |
|
| March 28, 2013 |
Exhibit 99.2 Preliminary Results of Phase 2 Dose-Ranging Study of AN2728 in Adolescents with Mild-to-Moderate Atopic Dermatitis (AN2728-AD-204) March 21, 2013 Safe Harbor Statement Certain items in this presentation and other matters discussed today or answers that may be given to questions asked could constitute forward-looking statements, including statements regarding the progress and timing of |
|
| March 28, 2013 |
Regulation FD Disclosure, Other Events - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission |
|
| March 21, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Em |
|
| March 21, 2013 |
Exhibit 99.2 Preliminary Results of Phase 2 Dose-Ranging Study of AN2728 in Adolescents with Mild-to-Moderate Atopic Dermatitis (AN2728-AD-204) March 21, 2013 Safe Harbor Statement Certain items in this presentation and other matters discussed today or answers that may be given to questions asked could constitute forward-looking statements, including statements regarding the progress and timing of |
|
| March 21, 2013 |
EX-99.1 2 a13-81281ex99d1.htm EX-99.1 Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 DOSE-RANGING STUDY OF AN2728 IN ADOLESCENTS WITH ATOPIC DERMATITIS Anacor Will Host a Conference Call Today 8am ET / 5am PT to Discuss Results Palo Alto, CA — March 21, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN272 |
|
| March 18, 2013 |
S-8 1 a13-73681s8.htm S-8 As filed with the Securities and Exchange Commission on March 18, 2013 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 25-1854385 (State or other jurisdiction of incorpor |
|
| March 15, 2013 |
Schedule 13D Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Anacor Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) DAVID L. STEPP VENROCK 3340 HILLVIEW AVENUE PALO ALTO, CALIFORNIA 94304 TELEPHONE: (650) 561-9580 (Name, Addr |
|
| March 14, 2013 |
ANACOR PHARMACEUTICALS REPORTS 2012 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS 2012 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Palo Alto, CA — March 14, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the fourth quarter and year ended December 31, 2012. “With the positive data from both Phase 3 trials of tavaborole for the treatment of onychomycosis, we anticipate filing an NDA around the mi |
|
| March 14, 2013 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Em |
|
| March 1, 2013 |
EX-99.2 3 a13-63031ex99d2.htm EX-99.2 Exhibit 99.2 Results from the Phase 3 Study (Study 302) of Tavaborole to Evaluate Efficacy and Safety in the Treatment of Onychomycosis February 28, 2013 Safe Harbor Statement Certain items in this presentation and other matters discussed today or answers that may be given to questions asked could constitute forward-looking statements, including statements reg |
|
| March 1, 2013 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM THE SECOND PHASE 3 TRIAL OF TAVABOROLE FOR ONYCHOMYCOSIS Anacor Will Host a Conference Call Today at 5pm ET to Discuss Results Palo Alto, CA – February 28, 2013 – Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302). Tavaborole is |
|
| March 1, 2013 |
ANAC / Anacor Pharmaceuticals, Inc. / GLAXOSMITHKLINE PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ANACOR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 032420 101 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS Telephone: +44 (0)208 047 5000 |
|
| March 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| February 20, 2013 |
ANAC / Anacor Pharmaceuticals, Inc. / KINGDON CAPITAL MANAGEMENT, L.L.C. Passive Investment SC 13G 1 d135827013-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) February 11, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2013 |
ANAC / Anacor Pharmaceuticals, Inc. / QVT Financial LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2013 |
ANAC / Anacor Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) January 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ANACOR PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this S |
|
| January 29, 2013 |
Exhibit 99.2 Results from the Phase 3 Study (Study 301) of Tavaborole to Evaluate Efficacy and Safety in the Treatment of Onychomycosis Safe Harbor Statement Certain items in this presentation and other matters discussed today or answers that may be given to questions asked could constitute forward-looking statements, including statements regarding the potential for approval based on the 301 study |
|
| January 29, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| January 29, 2013 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM THE FIRST OF TWO PHASE 3 TRIALS OF TAVABOROLE FOR ONYCHOMYCOSIS Anacor Will Host a Conference Call Today at 8am ET to Discuss Results Palo Alto, CA — January 29, 2013 — Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for o |
|
| January 23, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2013 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| January 18, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS Prospectus Supplement TABLE OF CONTENTS Table of Contents Filed Pursuant to rule 424(b)(5) Registration No. |
|
| December 14, 2012 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on December 14, 2012 Registration No. |
|
| December 14, 2012 |
Statement Regarding Computation of Ratios QuickLinks - Click here to rapidly navigate through this document Exhibit 12.1 Statement Regarding Computation of Ratios Year Ended December 31, Nine Months Ended September 30, 2012 2007 2008 2009 2010 2011 (In thousands, except ratio amounts) Earnings Loss before income taxes $ (11,611 ) $ (21,669 ) $ (24,854 ) $ (10,058 ) $ (47,944 ) $ (43,611 ) Interest expense 1,130 1,756 1,663 1,304 1,094 1,5 |
|
| December 13, 2012 |
8-K 1 a12-2930418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) |
|
| December 11, 2012 |
8-K 1 a12-2906618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) |
|
| December 11, 2012 |
Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL OF AN2728 IN ADOLESCENTS WITH ATOPIC DERMATITIS Anacor Will Host a Conference Call Today at 5pm ET / 2pm PT to Discuss Results Palo Alto, CA — December 10, 2012— Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from a Phase 2 safety, pharmacokinetics (PK), and efficacy trial of its boron-based ph |
|
| November 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| November 7, 2012 |
ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS Palo Alto, CA — November 7, 2012 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the third quarter ended September 30, 2012. “We are looking forward to announcing the results of our Phase 3 trials of tavaborole in onychomycosis in January 2013 for the first trial and approximately six |
|
| November 7, 2012 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| October 19, 2012 |
Schedule 13D Amendment No. 3 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Anacor Pharmaceuticals Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 032420101 (CUSIP number |
|
| October 18, 2012 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Prospectus Supplement Table of Contents Filed Pursuant to rule 424(b)(5) Registration No. |
|
| October 18, 2012 |
ANACOR PHARMACEUTICALS PRICES $24 MILLION PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 ANACOR PHARMACEUTICALS PRICES $24 MILLION PUBLIC OFFERING OF COMMON STOCK Palo Alto, CA — October 18, 2012 — Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that it has priced an underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $6.00 per share for gross proceeds of $24 million. Anacor has also granted the underwriter a 30-day option |
|
| October 18, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| October 18, 2012 |
4,000,000 Shares ANACOR PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT EX-1.1 2 a12-243333ex1d1.htm EX-1.1 Exhibit 1.1 4,000,000 Shares ANACOR PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT October 17, 2012 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Dear Sirs: 1. INTRODUCTORY. Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to Cowen and Company, LLC (the “U |
|
| October 17, 2012 |
Use these links to rapidly review the document TABLE OF CONTENTS Prospectus Supplement TABLE OF CONTENTS Table of Contents Filed Pursuant to rule 424(b)(5) Registration No. |
|
| October 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS E |
|
| October 9, 2012 |
ANACOR PHARMACEUTICALS ANNOUNCES THAT GSK HAS DISCONTINUED CLINICAL DEVELOPMENT OF GSK2251052 Exhibit 99.1 ANACOR PHARMACEUTICALS ANNOUNCES THAT GSK HAS DISCONTINUED CLINICAL DEVELOPMENT OF GSK2251052 Palo Alto, CA – October 5, 2012 – Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its collaboration partner GlaxoSmithKline (GSK) has discontinued clinical development of GSK2251052. As previously disclosed, GSK halted the most recent clinical trials of GSK2251052 due to the identif |
|
| September 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IR |
|
| September 25, 2012 |
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of James Marconi of Anacor Pharmaceuticals, Inc. |
|
| August 9, 2012 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Em |
|
| August 9, 2012 |
ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS Palo Alto, CA — August 9, 2012 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the second quarter ended June 30, 2012. “Our Phase 3 trials of tavaborole in onychomycosis are progressing well, and we expect to announce top-line results from the first of these trials in January 2013 and |
|
| July 3, 2012 |
ANAC / Anacor Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13G Passive Investment SC 13G 1 v317684sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 032420101 (CUSIP Number) June 22, 2012 (Date of Event Which Requires Filing of this Statement) Chec |
|
| June 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Empl |
|
| May 10, 2012 |
ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS EX-99.1 2 a12-116741ex99d1.htm EX-99.1 Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS Palo Alto, CA — May 10, 2012 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the first quarter ended March 31, 2012. “Our Phase 3 trials of tavaborole in onychomycosis are progressing well, with retention and compliance rates performing better tha |
|
| May 10, 2012 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Empl |
|
| April 18, 2012 |
DEF 14A 1 a2208838zdef14a.htm DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary P |
|
| March 15, 2012 |
S-8 1 a12-70651s8.htm S-8 As filed with the Securities and Exchange Commission on March 15, 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 25-1854385 (State or other jurisdiction of incorpor |
|
| March 13, 2012 |
ANACOR PHARMACEUTICALS REPORTS 2011 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Exhibit 99.1 ANACOR PHARMACEUTICALS REPORTS 2011 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Palo Alto, CA — March 13, 2012 — Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the fourth quarter and year ended December 31, 2011. “In 2011, we completed enrollment in two Phase 3 trials of tavaborole in onychomycosis, which keeps us on track to announce top-line data fr |
|
| March 13, 2012 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS Em |
|
| March 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2012 ANACOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34973 25-1854385 (State of incorporation) (Commission File No.) (IRS |
|
| February 15, 2012 |
ANAC / Anacor Pharmaceuticals, Inc. / RHO VENTURES IV LP - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| February 14, 2012 |
Schedule 13G Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ANACOR PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 032420101 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this S |
|
| February 9, 2012 |
Anacor Pharmaceuticals Announces the Sale of 3.25 Million Shares of Common Stock Exhibit 99.1 Anacor Pharmaceuticals Announces the Sale of 3.25 Million Shares of Common Stock PALO ALTO, California — February 8, 2012 — Anacor Pharmaceuticals (Nasdaq: ANAC), today announced the sale of 3.25 million shares of its common stock for gross proceeds of $21,450,000 pursuant to an underwriting agreement with Canaccord Genuity acting as the sole bookrunner. In addition, the Company has g |
